ImmunityBio partners with Middle East giants to launch ANKTIVA for cancer patients
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years
200+ HR leaders and CXOs convened to discuss workforce health, preventive care, and organisational wellbeing as strategic business priorities
Samsung Health users can now order medicines, book lab tests and online consultations through PharmEasy, along with 6 months of complimentary PharmEasy Plus membership
Our vision is to position India not just as a consumer of advanced simulation technologies but as a creator and exporter of them
The approval is based on the SWIFT and ANCHOR phase III trials, which demonstrated sustained efficacy with a twice-yearly dosing regimen
TED?A9 is part of S.Biomedics’ expanding pipeline of stem-cell-based therapies, developed using the company’s proprietary targeted embryonic stem cell differentiation platform
Wegovy is now offered in six weekly doses in the EU: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and the newly approved 7.2 mg dose
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
Subscribe To Our Newsletter & Stay Updated